middle.news
Vectus Opens FDA Pathway for VB0004 Lung Fibrosis Drug
9:12am on Wednesday 30th of September, 2026 AEST
•
Biotechnology
Read Story
Vectus Opens FDA Pathway for VB0004 Lung Fibrosis Drug
9:12am on Wednesday 30th of September, 2026 AEST
Key Points
FDA grants pre-IND Type B meeting request
Written responses expected by mid-November 2026
Vectus to finalise meeting package with Cardinal Health
VB0004 completed a Phase Ia study in healthy volunteers
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE